The U.S. biotech firm secures a supply agreement for its naloxone-based nasal spray in Canada.
Emergent BioSolutions has been awarded a contract by Canadian authorities to supply its naloxone-based nasal spray formulation. The agreement covers distribution for overdose reversal use.
Further details regarding volume, timing, or financial terms were not immediately available.
Helena covers corporate news for listed and private companies across Europe, from strategy shifts to leadership changes, with an eye for what a story signals about the broader market.
More from Helena Vásquez →
